Ivo Gut | Cancer Genomics Computational Studies | Outstanding Scientist Award

Posted on by Computational Biologists

Dr. Ivo Gut | Cancer Genomics Computational Studies |Outstanding Scientist Award

Director at Centro Nacional de Analisis Genomico, Spain.

Dr. Ivo Glynne Gut is an internationally recognized genomics expert, known for pioneering contributions in genome analysis, technology development, and translational research. Born in Basel, Switzerland, in 1960, he holds dual Swiss and British nationality and is fluent in German, English, French, and Spanish. Over a distinguished career spanning more than three decades, he has significantly influenced cancer genomics, rare diseases, epigenetics, and single-cell biology. Dr. Gut is currently the Director General and CEO of the Centro Nacional de Análisis Genómico (CNAG) in Barcelona, a leading genome analysis center in Southern Europe.

🎓Academic Background:

Dr. Ivo Glynne Gut embarked on his academic journey in the field of chemistry at the University of Basel, Switzerland. He earned his undergraduate degree in Chemistry in 1985, laying a strong foundation in the chemical sciences. Demonstrating a keen interest in the physical aspects of chemistry, he pursued and completed a Ph.D. in Physical Chemistry at the same institution in 1990. His doctoral studies equipped him with a profound understanding of the physical principles underlying chemical systems, setting the stage for his future contributions to genomics and molecular biology.

Profile:

💼 Professional Experience:

Dr. Ivo Glynne Gut is a renowned expert in genomics with a career spanning both academia and large-scale research infrastructures. He served as the Director of the Centro Nacional de Análisis Genómico (CNAG) in Spain, where he led high-throughput sequencing efforts for large genomic projects. Prior to that, he was a key scientist at the Centre National de Génotypage (CNG) in France, contributing to major European and international genomics initiatives. Dr. Gut has played a pivotal role in advancing personalized medicine, population genomics, and cancer research through his leadership and innovative approaches in genome analysis. His work bridges cutting-edge technology development with impactful biomedical applications.

🧪 Scientific and Research Excellence:

Dr. Gut’s scientific journey has been defined by a consistent drive to develop and apply innovative technologies to solve complex biomedical problems. His work has led to the creation of gold-standard tools, such as bisulphite pyrosequencing for DNA methylation analysis, and to the foundation of Epigenomics AG, which commercialized the Septin9 blood-based test for colon cancer detection. He played a key role in several landmark genome-wide association studies (GWAS) and was instrumental in uncovering critical genetic mutations in various cancers, including lung cancer, melanoma, and chronic lymphocytic leukemia (CLL). His recent focus on single-cell genomics has opened new frontiers in understanding immune cell dynamics in health and disease.

🌍 International Collaborations and Initiatives:

Dr. Gut’s influence extends globally through his participation in and leadership of major international initiatives. These include the International Cancer Genome Consortium (ICGC), International Human Epigenome Consortium (IHEC), and the 1+Million Genomes Initiative. He has chaired quality control working groups, led genomic infrastructure projects like RD-Connect and EASI-Genomics, and participated in European flagship programs in cancer and rare disease research. His involvement has shaped global best practices in genomic data analysis and policy.

🧠 Areas of Expertise:

His areas of specialization include genomics, bioinformatics, cancer biology, rare diseases, high-throughput sequencing, DNA/protein analysis methods, and the development of omics technologies. His interdisciplinary expertise has allowed him to lead from both technological and clinical fronts.

🏆Honors and Recognition:

Dr. Gut’s excellence has been widely recognized, notably with the “Stars of Europe” Prize awarded to the READNA consortium he coordinated. He also holds several prestigious fellowships and has served on influential scientific advisory boards for institutions including Genome Canada, ELIXIR, and the German Federal Ministry of Education and Research (BMBF). His patented inventions (24 in total) have had significant translational impact, further exemplifying his role as a bridge between discovery and real-world application.

🏥 Leadership and Institutional Impact:

As founding director of CNAG, Dr. Gut has overseen its evolution into a powerhouse of genomic research, managing a team of over 130 professionals and an annual budget of €14 million. Under his leadership, CNAG has achieved ISO certifications, produced over 400 studies annually, and contributed crucial genomic infrastructure and insight to the Spanish healthcare system, particularly in cancer and rare disease diagnostics. His role encompasses scientific strategy, operations, human resources, finance, and stakeholder engagement with ministries of research and health.

Publications:

  1. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, … Gut IG. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nature Genetics. 41(10):1094-1099, 2009. (Cited by 4396)

  2. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, … Gut IG. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nature Genetics. 40(8):955-962, 2008. (Cited by 3314)

  3. Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, … Gut IG. The repertoire of mutational signatures in human cancer. Nature. 578(7793):94-101, 2020. (Cited by 3096)

  4. Pan-cancer analysis of whole genomes. Nature. 578(7793):82-93, 2020. (Cited by 2707)

  5. Moffatt MF, Gut IG, Demenais F, Strachan DP, Bouzigon E, Heath S, … A large-scale, consortium-based genomewide association study of asthma. New England Journal of Medicine. 363(13):1211-1221, 2010. (Cited by 2519)

  6. Rhie A, McCarthy SA, Fedrigo O, Damas J, Formenti G, Koren S, … Gut IG. Towards complete and error-free genome assemblies of all vertebrate species. Nature. 592(7856):737-746, 2021. (Cited by 2443)

  7. International network of cancer genome projects. International Cancer Genome Consortium. Nature. 464(7291):993, 2010. (Cited by 2431)

  8. SEARCH Collaborative Group, Gut IG. SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study. New England Journal of Medicine. 359(8):789-799, 2008. (Cited by 2361)

  9. Lappalainen T, Sammeth M, Friedländer MR, ‘t Hoen PAC, Monlong J, … Gut IG. Transcriptome and genome sequencing uncovers functional variation in humans. Nature. 501(7468):506-511, 2013. (Cited by 2148)

  10. Moffatt MF, Kabesch M, Liang L, Dixon AL, Strachan D, Heath S, … Gut IG. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature. 448(7152):470-473, 2007. (Cited by 2023)

  11. Puente XS, Pinyol M, Quesada V, Conde L, Ordóñez GR, Villamor N, … Gut IG. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 475(7354):101-105, 2011. (Cited by 1980)

  12. Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D, … Gut IG. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature. 452(7187):633-637, 2008. (Cited by 1514)

  13. Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, … Gut IG. Genome-wide association study identifies eight loci associated with blood pressure. Nature Genetics. 41(6):666-676, 2009. (Cited by 1465)

  14. Quesada V, Conde L, Villamor N, Ordóñez GR, Jares P, Bassaganyas L, … Gut IG. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nature Genetics. 44(1):47-52, 2012. (Cited by 1306)

  15. Dixon AL, Liang L, Moffatt MF, Chen W, Heath S, Wong KCC, Taylor J, … Gut IG. A genome-wide association study of global gene expression. Nature Genetics. 39(10):1202-1207, 2007. (Cited by 1184)

  16. Puente XS, Beà S, Valdés-Mas R, Villamor N, Gutiérrez-Abril J, … Gut IG. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature. 526(7574):519-524, 2015. (Cited by 1094)

  17. Gerstung M, Jolly C, Leshchiner I, Dentro SC, Gonzalez S, Rosebrock D, … Gut IG. The evolutionary history of 2,658 cancers. Nature. 578(7793):122-128, 2020. (Cited by 1066)

  18. Prado-Martinez J, Sudmant PH, Kidd JM, Li H, Kelley JL, … Gut IG. Great ape genetic diversity and population history. Nature. 499(7459):471-475, 2013. (Cited by 1009)

  19. Heyn H, Li N, Ferreira HJ, Moran S, Pisano DG, Gomez A, Diez J, … Gut IG. Distinct DNA methylomes of newborns and centenarians. Proceedings of the National Academy of Sciences. 109(26):10522-10527, 2012. (Cited by 932)

  20. Tost J, Gut IG. DNA methylation analysis by pyrosequencing. Nature Protocols. 2(9):2265-2275, 2007. (Cited by 868)

Shuying FENG | Functional Genomics | Best Researcher Award

Posted on by Computational Biologists

Prof. Shuying FENG | Functional Genomics | Best Researcher Award

Director at Henan University of Chinese Medicine, China.

Dr. Shuying Feng is a Professor, PhD, and Postdoctoral Supervisor at Henan University of Chinese Medicine, where he leads several key research centers focused on functional and special medical foods. A nationally recognized expert in traditional Chinese medicine, his work integrates nanotechnology, probiotic fermentation, gene editing, and the medical application of natural products. Dr. Shuying Feng has published over 100 papers (90+ SCI-indexed), holds 21 national invention patents, and has directed numerous national and provincial projects. He is also a distinguished academic leader, mentor, and recipient of multiple scientific and technological awards.

🎓 Academic Background :

Dr. Shuying Feng is a highly accomplished Professor and Doctoral/Postdoctoral Supervisor at Henan University of Chinese Medicine. Holding a PhD and serving as a leading scholar in his field, Dr. Shuying Feng is also a member of the Communist Party of China. He currently leads several prominent research institutions, including the Henan Engineering Research Center for Special Medical Foods of Traditional Chinese Medicine, and serves as Executive Director of the Institute of Functional Foods and Medicine-Food Homologous Research. His academic leadership has significantly influenced the advancement of traditional Chinese medicine and functional food research across Henan Province and beyond.

Profile:

Professional Experience:

Dr. Shuying Feng has extensive professional experience as a professor, researcher, and academic leader in the field of traditional Chinese medicine and functional foods. He currently serves as Director of multiple research centers, including the Henan Engineering Research Center for Special Medical Foods, and holds executive roles at key provincial and municipal laboratories. Over his career, he has led more than 30 national, provincial, and industry-funded research projects, secured significant research funding, and guided numerous graduate and postdoctoral researchers. His work has resulted in over 100 publications, 21 national patents, and wide-ranging contributions to both academic and industrial advancements in medical food innovation.

🔬 Research Interests:

Dr. Shuying Feng’s research spans several pioneering fields within biomedical science and traditional medicine. His primary areas of interest include the development of functional and special medical foods, the nanoization and probiotic fermentation enhancement of traditional Chinese medicine, gene editing and its applications in microalgae, and the medical applications of bee products. His multidisciplinary approach bridges ancient medicinal wisdom with cutting-edge biotechnology, driving innovation in both health and food sciences.

🏅 Honors & Recognition:

Dr. Shuying Feng has been recognized with numerous accolades, including the title of Distinguished Professor of Henan Province, High-Level Talent (Category C), Academic and Technical Leader by the Henan Department of Education, and Outstanding Young Backbone Teacher in Higher Education. At the city level, he has been named an Excellent Scientific and Technological Talent. These honors underscore his contributions to both academic excellence and public service in the field of medical science.

🏛️ Leadership & Roles:

Beyond his research and teaching, Dr. Feng holds influential roles in academic societies. He is Vice Chairman of the Tumor Cell Professional Committee of the Henan Cell Biology Society and a council member of both the Fermentation Research Committee under the World Federation of Chinese Medicine Societies and the Henan Biochemistry and Molecular Biology Society. These leadership positions highlight his commitment to collaborative scientific advancement and community engagement.

Publications:

  • Meng, Y., Si, Y., Guo, T., Sun, K., & Feng, S. (2025). Ethoxychelerythrine as a potential therapeutic strategy targets PI3K/AKT/mTOR induced mitochondrial apoptosis in the treatment of colorectal cancer. Scientific Reports.
    🔹 Citations: 1

  • Ji, C., Li, S., Hu, C., Yin, S., & Feng, S. (2024). Traditional Chinese medicine as a promising choice for future control of PEDV. (Journal name not specified).
    🔹 Citations: 0

  • Zhang, B., Wang, Q., Zhang, Y., Wang, B., & Feng, S. (2024). Treatment of insomnia with traditional Chinese medicine presents a promising prospect. (Journal name not specified).
    🔹 Citations: 0

  • Yang, Y., Li, S., Shi, W., Lu, B., & Feng, S. (2024). Pterostilbene suppresses the growth of esophageal squamous cell carcinoma by inhibiting glycolysis and PKM2/STAT3/c-MYC signaling pathway. International Immunopharmacology.
    🔹 Citations: 1

  • Wei, W., Guo, T., Fan, W., Ma, W., & Feng, S. (2024). Integrative analysis of metabolome and transcriptome provides new insights into functional components of Lilii Bulbus. Chinese Herbal Medicines.
    🔹 Citations: 5

Eyachew Misganew Tegaw | AI in Personalized Medicine | Best Researcher Award

Posted on by Computational Biologists

Assist. Prof. Dr. Eyachew Misganew Tegaw | AI in Personalized Medicine | Best Researcher Award

Assistant Professor of Medical Physics at  Debre Tabor University, Ethiopia.

Dr. Eyachew Misganew Tegaw is an Assistant Professor of Medical Physics at Debre Tabor University, Ethiopia. He earned his Ph.D. from Tehran University of Medical Sciences, specializing in intraoperative radiotherapy using nanoparticles for breast cancer treatment. His research spans medical imaging, radiation therapy, nanomedicine, and AI applications in oncology. Dr. Eyachew Misganew Tegaw has published extensively in peer-reviewed journals and actively contributes to scientific advancement through research, mentorship, and international collaboration.

👨‍🎓 Educational Background:

Eyachew Misganew Tegaw holds a Ph.D. in Medical Physics from the Tehran University of Medical Sciences (TUMS), Iran, where he specialized in intraoperative radiotherapy (IORT) using nanoparticles for breast cancer treatment. His academic journey began with a B.Sc. in Applied Physics from the University of Gondar, followed by an M.Sc. in Condensed Matter Physics from Mekelle University. Across these programs, he built a strong foundation in quantum mechanics, computational physics, and radiation therapy physics, gaining multidisciplinary expertise in both theoretical and applied domains.

Profile:

👨‍🏫 Professional Experience:

With over a decade of academic service, Dr. Eyachew Misganew Tegaw currently serves as an Assistant Professor in the Department of Physics at Debre Tabor University, Ethiopia. He previously held the position of Lecturer at the same institution, actively contributing to curriculum development and student mentorship. His leadership experience includes a two-year term as Department Head and three years as Chair of the Ethiopian Space Science Society (Debre Tabor Branch), showcasing his commitment to both academic and community development.

🧪 Research Interests:

Dr. Eyachew Misganew Tegaw is a highly driven researcher with diverse interests spanning medical physics, radiotherapy technologies, medical imaging, radiation dosimetry, nanomedicine, Monte Carlo simulations, and artificial intelligence. His work integrates cutting-edge approaches like deep learning and machine learning with traditional medical physics techniques, aiming to enhance cancer treatment planning and medical imaging. He is especially passionate about nanoparticle-enhanced therapies and computational modeling for improved patient outcomes in oncology.

🔍 Areas for Improvement:

While Dr. Eyachew Misganew Tegaw has made significant strides in academic research, increased visibility through invited talks, expanded international partnerships, and higher engagement in translational clinical projects could further enhance his research impact. Diversifying funding sources and mentoring emerging researchers may also solidify his standing in the global scientific community.

📚 Scientific Contributions

Dr. Eyachew has authored and co-authored numerous peer-reviewed journal articles in high-impact scientific journals. His publications cover a wide range of topics such as Monte Carlo simulations for radiotherapy, nanoparticle-enhanced imaging and treatment, and explainable AI in oncology. Notable among his recent works is a 2025 article in Scientific Reports comparing survival outcomes in breast cancer surgery, and another accepted paper focusing on AI for lung cancer survival prediction. His systematic reviews and meta-analyses have also significantly contributed to evidence-based practice in cancer diagnosis and therapy.

Publications:

  1. Diagnostic performance of mammography and ultrasound in breast cancer: A systematic review and meta-analysis
    Journal of Ultrasound, 2023

  2. Dosimetric characteristics of the INTRABEAM® system with spherical applicators in the presence of air gaps and tissue heterogeneities
    Radiation and Environmental Biophysics, 2020

  3. Techniques for generating attenuation map using cardiac SPECT emission data only: A systematic review
    Annals of Nuclear Medicine, 2019

  4. Molecular imaging approaches in the diagnosis of breast cancer: A systematic review and meta-analysis
    Iranian Journal of Nuclear Medicine, 2020

  5. Comparison of organs at risk doses between deep inspiration breath-hold and free-breathing techniques during radiotherapy of left-sided breast cancer: A meta-analysis
    Polish Journal of Medical Physics and Engineering, 2022

  6. Gold-nanoparticle-enriched breast tissue in breast cancer treatment using the INTRABEAM® system: A Monte Carlo study
    Radiation and Environmental Biophysics, 2022

  7. Dosimetric effect of nanoparticles in the breast cancer treatment using INTRABEAM® system with spherical applicators in the presence of tissue heterogeneities: A Monte Carlo study
    Biomedical Physics & Engineering Express, 2021

  8. A comparison between EGSnrc/Epp and MCNP in simulation of dosimetric parameters for radiotherapy applications
    Journal of Biomedical Physics & Engineering, 2021

  9. Explainable machine learning to compare the overall survival status between patients receiving mastectomy and breast conserving surgeries
    Scientific Reports, 2025

  10. Attenuation correction for dedicated cardiac SPECT imaging without using transmission data
    Molecular Imaging and Radionuclide Therapy, 2023

  11. Comparative study between EPID and CBCT for radiation treatment verifications
    Iranian Journal of Medical Physics, 2018

Hua Zhu | AI in Drug Discovery | Best Researcher Award

Posted on by Computational Biologists

Prof. Hua Zhu | AI in Drug Discovery | Best Researcher Award   

Researcher, Ph.D. Supervisor at  Beijing Cancer Hospital & Institute, Peking University, China.
Prof. Hua Zhu is a distinguished researcher and full professor at the Department of Nuclear Medicine, Beijing Cancer Hospital & Institute, Peking University. With a focused career in molecular imaging and nuclear medicine, Prof. Zhu has made pioneering contributions to the clinical translation of cancer theranostics. His extensive work in radiopharmaceuticals, multimodality molecular probes, and targeted delivery systems places him among the leading scientists in his field.

🎓 Academic Background:

Prof. Zhu earned his Bachelor of Science degree in Applied Chemistry from Nanjing Normal University in 2006, followed by a Ph.D. in Inorganic Chemistry (specializing in Radiopharmaceuticals) from the Shanghai Institute of Applied Physics, Chinese Academy of Sciences in 2011. He also enriched his academic perspective through a visiting assistant professorship at Stanford University from 2014 to 2015.

Profile:

Professional Experience:

Prof. Hua Zhu is a full professor at the Department of Nuclear Medicine, Beijing Cancer Hospital & Institute, Peking University. He has over a decade of professional experience in the development of molecular imaging agents and targeted radiopharmaceuticals for cancer diagnosis and therapy. He has led multiple national-level research projects and previously served as a visiting assistant professor at Stanford University, contributing to international research collaboration. His expertise spans from radionuclide production to clinical translation, and he actively holds leadership roles in key academic societies related to nuclear medicine and imaging science.

🧪 Research Focus:

Prof. Zhu’s research is dedicated to the development of molecular imaging tools and targeted delivery systems for cancer diagnosis and treatment. His focus areas include the production and application of solid-target based radionuclides such as ⁶⁴Cu, ⁸⁹Zr, and ¹²⁴I, and the design of multimodal imaging probes. His efforts are instrumental in bridging the gap between bench research and clinical oncology.

🏆 Academic Honors:

Prof. Zhu has received numerous prestigious honors that recognize his research excellence and leadership in the field:

  • 🌟 National-level Young Talent (2023)

  • 🧠 Young Beijing Scholar (2024)

  • 📘 Boya Young Scholar (2025)

  • 🌆 “Bai Qian Wan” Talent of Beijing (2019)

  • 💫 Beijing Young Top-notch Talent (2018)

  • ✨ Beijing Nova Program (2017)

🔬 Research Leadership:

As a principal investigator, Prof. Zhu leads four National Natural Science Foundation of China (NSFC) projects and over ten national/provincial initiatives. His work exemplifies effective leadership in interdisciplinary and cross-institutional collaboration.

Publications:

  1. Detectability of Al¹⁸F-NOTA-HER2-BCH PET for Nodal Metastases in Patients With HER2-Positive Breast Cancer
    Clinical Nuclear Medicine, 2025

  2. Construction of Bispecific T-Cell Engager Radiotracer and Its Micro-PET Evaluation in Pancreatic Cancer
    Molecular Pharmaceutics, 2025

  3. Radiolabelled Anti-PD-L1 Peptide PET/CT in Predicting the Efficacy of Neoadjuvant Immunotherapy Combined With Chemotherapy in Resectable Non-Small Cell Lung Cancer
    Annals of Nuclear Medicine, 2025

  4. [¹⁷⁷Lu]Lu-XYIMSR-01: A Novel CAIX-Targeted Radiotherapeutic for Enhanced Treatment of Malignant Glioma
    Bioconjugate Chemistry, 2025

  5. A Whole-Body Imaging Technique for Tumor-Specific Diagnostics and Screening of B7H3-Targeted Therapies
    Journal of Clinical Investigation, 2025 (Open Access)

  6. Development and First-in-Human Evaluation of a Site-Specific [¹⁸F]-Labeled PD-L1 Nanobody PET Radiotracer for Noninvasive Imaging in NSCLC
    Bioorganic Chemistry, 2025

  7. Radioiodinated Nanobody ImmunoPET Probe for In Vivo Detection of CD147 in Pan-Cancer
    European Journal of Nuclear Medicine and Molecular Imaging, 2025

  8. Strategies for Specific Multimodal Imaging of Cancer-Associated Fibroblasts and Applications in Theranostics of Cancer
    Open Access Review

  9. Efficacy of Radiolabelled PD-L1-Targeted Nanobody in Predicting and Evaluating the Combined Immunotherapy and Chemotherapy for Resectable Non-Small Cell Lung Cancer
    European Journal of Nuclear Medicine and Molecular Imaging, 2025

  10. Recent Advances in Emerging Radiopharmaceuticals and the Challenges in Radiochemistry and Analytical Chemistry
    Review Article, 2025

Abdelrahman Elgohr | Bioinformatics | Best Researcher Award

Posted on by Computational Biologists

Dr.Abdelrahman Elgohr | Bioinformatics | Best Research Article Award

Mechatronics engineering department, faculty of engineering at Horus University Egypt, Egypt.

Dr. Abdelrahman Tarek Elgohr is an Assistant Lecturer in Mechatronics Engineering at Horus University, Egypt, with a strong research focus on robotics, artificial intelligence, and brain-computer interfaces. He holds an MSc from Zagazig University and is currently pursuing his PhD at Mansoura University. Dr. Elgohr has published extensively in top-tier journals, contributed to cutting-edge work on robotic arm optimization and EEG signal analysis, and is a certified Huawei AI instructor. His blend of academic leadership, technical expertise, and innovative research makes him a rising figure in applied mechatronics and intelligent systems.

🎓 Academic Background:

Dr. Abdelrahman Tarek Elgohr is a distinguished Mechatronics Engineer and academic, currently serving as an Assistant Lecturer at the Faculty of Engineering, Horus University, Egypt. He holds a Master of Science in Mechatronics Engineering from Zagazig University, where he conducted advanced research on brain-controlled robotic systems. Currently, he is pursuing a Ph.D. in Mechatronics Engineering at Mansoura University, having achieved excellence in courses covering nonlinear control systems, intelligent technologies, and advanced robotics.

Profile:

📚 Research Expertise:

Dr. Elgohr’s research lies at the dynamic intersection of robotics, artificial intelligence, and biomedical systems. His master’s thesis focused on the development of a brain-controlled robotic arm using deep learning and optimization algorithms, demonstrating innovation in both AI application and mechanical control. He has authored over 13 peer-reviewed publications in internationally indexed journals such as Elsevier, Wiley, IEEE Xplore, and the Journal of Engineering Research, covering diverse topics from EEG signal classification to sustainable energy systems and robotic path planning.

🧠 Teaching and Academic Contributions:

With over six years of teaching experience at Horus University, Dr. Elgohr has played a vital role in shaping the academic journey of future engineers. He teaches a broad range of courses, including Robotics Engineering, Motion Control, CAD Design, and Electrical Circuits. He also serves as the Head of the Robotics Laboratory and contributes to quality assurance, student advising, and curriculum development—particularly in the university’s Artificial Intelligence program.

🛠️ Technical Skills and Certifications:

Dr. Elgohr possesses strong technical proficiency across several platforms and tools. He is skilled in programming languages such as C, Python, and MATLAB, and has hands-on experience with TensorFlow and SolidWorks. His certifications include Huawei HCIA AI Instructor, SolidWorks Associate, Siemens PLC Programming, and multiple professional development courses offered by DAAD Egypt, including proposal writing and fundraising.

🌟 Achievements and Roles:

Beyond research and teaching, Dr. Elgohr is actively engaged in academic service. He has advised over 80 students, served on examination and academic scheduling committees, and is an IEEE Horus Student Branch monitor. Notably, he is the first Huawei AI Certified Instructor at Horus University. His academic leadership and organizational skills continue to strengthen the university’s robotics and AI ecosystem.

Publications:

  1. A Comprehensive Review on Hybridization in Sustainable Desalination Systems
    Membranes, 2025.

  2. Path Planning for a 6 DoF Robotic Arm Based on Whale Optimization Algorithm and Genetic Algorithm
    Journal of Engineering Research, 2023.

  3. Trajectory Optimization for a 6 DOF Robotic Arm Based on Reachability Time
    Annals of Emerging Technologies in Computing, 2024.

  4. Enhancing Conical Solar Stills with Aluminum Ball Energy Storage: Optimal Distance for Improved Performance
    Journal of Energy Storage, 2024.

  5. Multi-Classification Model for Brain Tumor Early Prediction Based on Deep Learning Techniques
    Journal of Engineering Research, 2024.

  6. A Novel Hybrid Deep Neural Network Classifier for EEG Emotional Brain Signals
    International Journal of Advanced Computer Science and Applications, 2024.

  7. Whale-Based Trajectory Optimization Algorithm for 6 DOF Robotic Arm
    Annals of Emerging Technologies in Computing, 2024.

  8. Modeling of Heat Transfer and Airflow Inside Evacuated Tube Collector with Heat Storage Media: Experimental Validation Powered by Artificial Neural Network
    Heat Transfer, 2025.

  9. Performance Evaluation of a Standalone Solar-Powered Irrigation System in Desert Regions Using PVsyst: A Comprehensive Analysis
    25th International Middle East Power System Conference (MEPCON), 2024.

  10. Comparative Analysis for Accurate Multi-Classification of Brain Tumor Based on Significant Deep Learning Models
    Computers in Biology and Medicine, 2025.

  11. Advancements in Photovoltaic Technology: A Comprehensive Review of Recent Advances and Future Prospects
    Energy Conversion and Management: X, 2025.

  12. Trajectory Optimization for 6 DOF Robotic Arm Using WOA, GA, and Novel WGA Techniques
    Results in Engineering, 2025.

  13. Innovative Electrode Design and Catalytic Enhancement for High-Efficiency Hydrogen Production in Renewable Energy Systems
    Energy Sources, Part A: Recovery, Utilization, and Environmental Effects, 2025.

  14. Early Lung Cancer Detection with a Fusion of Inception V3 and Vision Transformers: A Binary Classification Study
    International Conference on Future Telecommunications and Artificial Intelligence (FutureTech), 2024.

  15. Enhancing Urban Park Connectivity and User Experience Through Space Syntax Analysis with Environmental Performance Analysis: A Case Study in New Damietta City, Egypt
    Urban Studies – Egypt, 2024.

Nazanin Zounemat-Kermani | Computational Systems Medicine | Best Researcher Award

Posted on by Computational Biologists

Dr Nazanin Zounemat-Kermani | Computational Systems Medicine | Best Researcher Award

Dr. Nazanin Zounemat-Kermani is an accomplished biomedical data scientist whose research stands at the forefront of precision medicine, respiratory disease, and artificial intelligence. Currently serving as a Postdoctoral Research Associate at both the National Heart and Lung Institute (NHLI) and the Data Science Institute (DSI) at Imperial College London, she has earned international recognition for her leadership in multi-omics data integration and machine learning applications in health sciences.

Profile:

🎓 Educational Background:

Dr. Kermani’s academic journey reflects a rare interdisciplinary blend of computer science and biomedical research. She holds a PhD in Biomedicine from Imperial College London (2020), following dual master’s degrees in Artificial Intelligence from the University of Amsterdam (2011) and Machine Learning and Robotics from the University of Tehran (2004). Her academic roots trace back to a Bachelor of Engineering in Software Engineering from Ferdowsi University of Mashhad (2002).

💼 Professional Experience:

Since 2020, Dr. Kermani has worked as a Postdoctoral Research Associate at Imperial College London, after several years as a Research Assistant and PhD candidate in Zoltan Takats’ Lab. Her academic trajectory within one of the world’s top institutions reflects both her scientific rigor and leadership capabilities.

🎓🤝 Academic Mentorship:

Dr. Nazanin Zounemat-Kermani is widely respected not only for her scientific contributions but also for her unwavering commitment to mentorship and academic leadership. Throughout her career, she has actively nurtured the growth of early-career scientists, postdoctoral researchers, and graduate students. As a senior member of interdisciplinary consortia such as AI-RESPIRE, PRISM, and U-BIOPRED, she has led cross-functional teams spanning clinical science, data engineering, and machine learning—mentoring junior colleagues in both technical development and scientific publishing. Her leadership style is inclusive and empowering, emphasizing hands-on guidance in areas such as statistical modeling, research communication, and responsible data science.

🏆 Awards and Honors:

Dr. Kermani has received numerous accolades, including the MSACL Young Investigator Award (2016), Scholar Awards from the American Thoracic Society (2022, 2023), and multiple research grants from prestigious bodies such as the UKRI, MRC, and EPSRC. She has also been invited to present her research by eminent scholars at institutions like Oxford University and Amsterdam UMC.

🌍 Global Projects and Leadership

Dr. Kermani has led and contributed to numerous high-impact international projects, including:

  • RASP-UK: She developed a robust data management platform supporting clinical and omics data integration for asthma research.

  • PIONEER: Co-led machine learning initiatives in prostate cancer, resulting in a key senior-author publication.

  • U-BIOPRED: Coordinated Europe’s largest severe asthma cohort study, publishing over 20 peer-reviewed articles and acting as corresponding author on influential multi-omics studies.

  • UK-Korea PRISM: Leads cross-national efforts in asthma pathophysiology using advanced analytics and single-cell data.

  • AI-RESPIRE: Heads AI model development for environmental and physiological time-series data, mentoring early-career researchers.

  • DeVENT and PROmics: Oversees analysis in critical care and deep learning integration in patient-reported outcomes.

📚 Publications:

  1. CC16 Confers Protection Against Influenza A Virus Infection in Human Airway Epithelium
    H. Kimura, N.Z. Kermani, N. Kimura, M.M. Siddiq, D. Francisco, I.M. Adcock, et al.
    American Journal of Respiratory and Critical Care Medicine, Vol. 211 (Abstracts), 2025.

  2. Distinct Single-Cell Transcriptional Profile in CD4⁺ T-Lymphocytes Among Obese Children With Asthma
    V. Tejwani, R. Wang, A. Villabona-Rueda, K. Suresh, T.D. Wu, I.M. Adcock, et al.
    American Journal of Physiology – Lung Cellular and Molecular Physiology, Vol. 328(3), 2025.

  3. Female Sex Hormones and the Oral Contraceptive Pill Modulate Asthma Severity Through GLUT-1
    A.C. Brown, O.R. Carroll, J.R. Mayall, N. Zounemat-Kermani, S.L.E. Vinzenz, et al.
    Mucosal Immunology, 2025.

  4. Neutrophilic Inflammation in Sputum or Blood Does Not Define a Clinically Distinct Asthma Phenotype in ATLANTIS
    P.J.M. Kuks, T.M. Kole, M. Kraft, S. Siddiqui, L.M. Fabbri, K.F. Rabe, A. Papi, et al.
    ERJ Open Research, Vol. 11(1), 2025.

  5. The Role of WNT5a and TGF‐β1 in Airway Remodelling and Severe Asthma
    T. Daud, S. Roberts, N. Zounemat-Kermani, M. Richardson, L.G. Heaney, et al.
    Allergy, 2025.

  6. Clinical Importance of Patient-Reported Outcome Measures in Severe Asthma: Results from U-BIOPRED
    R. Meys, F.M.E. Franssen, A.J. Van ‘t Hul, P.S. Bakke, M. Caruso, B. Dahlén, et al.
    Health and Quality of Life Outcomes, Vol. 22(1), Article 109, 2024.

  7. Radiomultiomics: Quantitative CT Clusters of Severe Asthma Associated With Multiomics
    N.Z. Kermani, K.F. Chung, G. Macis, G. Santini, F.A.A. Clemeno, A. Versi, K. Sun, et al.
    European Respiratory Journal, Vol. 64(5), 2024.

  8. S12 Association Between Disease Duration and FEV1 in Severe Asthma Phenotypes and Endotypes
    F. Yang, N. Zounemat-Kermani, P. Dixey, I.M. Adcock, C.I. Bloom, K.F. Chung
    Thorax, Vol. 79(Suppl 2), A15–A16, 2024.

  9. S120 Post-Hoc Analysis of Transcriptomic and Clinical Predictors of Remission in the ATLANTIS Cohort
    A.A. Kumar, T.M. Kole, M.C. Nawijn, K.F. Rabe, A. Papi, C. Brightling, D. Singh, et al.
    Thorax, Vol. 79(Suppl 2), A83–A84, 2024.

  10. Discovery and Validation of a Volatile Signature of Eosinophilic Airway Inflammation in Asthma
    R. Peltrini, R.L. Cordell, M. Wilde, S. Abuhelal, E. Quek, N. Zounemat-Kermani, et al.
    American Journal of Respiratory and Critical Care Medicine, Vol. 210(9), pp. 1101–1112, 2024.

  11. Cardiovascular Events in CML Patients Treated With Nilotinib: Validation of the HFA-ICOS Baseline Risk Score
    M. Andres, F. Fernando, S. Claudiani, N. Kermani, G. Ceccarelli, J. Apperley, et al.
    European Heart Journal, Vol. 45(Suppl 1), ehae666.3169, 2024.

  12. Scientific Business Abstracts
    F. Cooles, G. Vidal-Pedrola, N. Naamane, A. Pratt, B. Barron-Millar, et al.
    QJM: An International Journal of Medicine, Article hcae157, 2024.

  13. A Severe Asthma Phenotype of Excessive Airway Haemophilus influenzae Relative Abundance Associated With Sputum Neutrophilia
    A. Versi, A. Azim, F.X. Ivan, M.I. Abdel-Aziz, S. Bates, J. Riley, M. Uddin, et al.
    Clinical and Translational Medicine, Vol. 14(9), e70007, 2024.

  14. Host-Microbial Interactions Differ With Age of Asthma Onset
    A. Versi, A. Azim, F.X. Ivan, M.I. Abdel-Aziz, S. Bates, J. Riley, et al.
    European Respiratory Journal, 2024.

  15. Cardiovascular Events in CML Patients Treated With Nilotinib: Validation of the HFA-ICOS Baseline Risk Score
    F. Fernando, M.S. Andres, S. Claudiani, N.Z. Kermani, G. Ceccarelli, A.J. Innes, et al.
    Cardio-Oncology, Vol. 10(1), Article 42, 2024.

  16. Endotypes of Severe Neutrophilic and Eosinophilic Asthma From Multi-Omics Integration of U-BIOPRED Sputum Samples
    N.Z. Kermani, C.X. Li, A. Versi, Y. Badi, K. Sun, M.I. Abdel-Aziz, M. Bonatti, et al.
    Clinical and Translational Medicine, Vol. 14(7), e1771, 2024.

  17. IL-33 Induced Gene Expression in Activated Th2 Effector Cells Is Dependent on IL-1RL1 Haplotype and Asthma Status
    A.K.S. Jayalatha, M.E. Ketelaar, L. Hesse, Y.E. Badi, N. Zounemat-Kermani, et al.
    European Respiratory Journal, Vol. 63(6), 2024.

  18. Comparison of Asthma Phenotypes in Severe Asthma Cohorts (SARP, U-BIOPRED, ProAR and COREA) From Four Continents
    S.Y. Park, S. Fowler, D.E. Shaw, I.M. Adcock, A.R. Sousa, R. Djukanovic, et al.
    Allergy, Asthma & Immunology Research, Vol. 16(4), p. 338, 2024.

  19. Enose-Derived Response Clusters in Severe Asthmatics Treated With Anti-IL5/5R Biologics
    P. Dixey, N. Zounemat-Kermani, K. Raby, P.K. Bhavsar, K.F. Chung
    B16. Novel Insights Into Asthma Pathogenesis, A3013, 2024.

  20. Association of CC16 Expression in the Airways With Signature Expression of Multi-Omics Data
    H. Kimura, N.Z. Kermani, I.M. Adcock, K.F. Chung, M. Kraft
    D91. Bridging the Gap: Translational Studies in ARDS, Pneumonia, and Sepsis, 2024.